Table 1.
Characteristics of Patients Divided by Categories of Hs‐cTnT
| General Characteristics | All Patients (N=1336) | Hs‐cTnT Category, pg/mL | P Value | |||
|---|---|---|---|---|---|---|
| <3.0 (n=576) | 3.0–5.0 (n=270) | 5.1–9.0 (n=257) | ≥9.1 (n=233) | |||
| Age, y | 65±11 | 61±10 | 66±11 a | 69±9.1 a,d | 72±10 a,d,g | <.001 |
| Men, % | 49.9 | 39.8 | 50.4 | 54.1 | 51.5 | <.001 |
| Body mass index, kg/m2 | 24.5±3.6 | 24.4±3.7 | 24.3±3.8 | 25.0±3.5 | 24.5±3.3 | 0.108 |
| Body surface area, m2 | 1.61±0.19 | 1.62±0.18 | 1.61±0.20 | 1.63±0.18 | 1.59±0.18 | .120 |
| Current smokers, % | 11.8 | 9.7 | 13.7 | 11.3 | 9.4 | .312 |
| Habitual drinkers, % | 23.3 | 23.4 | 25.9 | 25.3 | 17.6 | .118 |
| Hyperlipidemia, % | 65.9 | 64.9 | 66.3 | 61.9 | 72.1 | .107 |
| Diabetes, % | 24.9 | 21.0 | 23.0 | 28.8 | 32.2 | .003 |
| History of CVD, % | 19.4 | 14.4 | 17.0 | 25.3 | 27.9 | <.001 |
| eGFR, mL/min/1.73 m2 | 71.4±17.5 | 77.8±15.5 | 72.9±14.7 a | 67.5±16.3 a,d | 58.0±18.1 a,d,f | <.001 |
| Atrial fibrillation, % | 5.1 | 4.0 | 3.7 | 6.6 | 7.7 | .069 |
| Sleep apnea syndrome, % | 4.4 | 4.7 | 3.0 | 5.8 | 3.9 | .416 |
| Use of antihypertensive medication, % | 82.7 | 77.6 | 84.4 | 85.2 | 90.6 | <.001 |
| NT‐proBNP, pg/mL | 57.1 (28.6–112.3) | 39.2 (19.7–68.3) | 56.5 a (29.3–106.8) | 72.7 a,d (38.6–127.6) | 143.9 a,d,f (64.9–297.0) | <.001 |
| BP parameters, mm Hg | ||||||
| Office SBP | 140±16 | 140±16 | 141±16 | 140±17 | 142±19 | .418 |
| Office DBP | 80±11 | 83±10 | 80±10 c | 79±11 a | 76±12 a,d | <.001 |
| MEave in SBP | 135±14 | 133±13 | 136±14 c | 136±14 b | 141±17 a,d,g | <.001 |
| MEave in DBP | 76±9.6 | 77±9.1 | 76±9.4 | 75±9.4 b | 74±11 a | <.001 |
| Echocardiographic profiles | ||||||
| LVIDd, mm | 45.8±5.3 | 45.7±4.5 | 46.0±5.0 | 45.9±5.4 | 45.7±5.4 | .779 |
| LVIDd/BSA, mm/m2 | 28.6±3.5 | 28.4±3.1 | 28.9±3.8 | 28.4±3.7 | 29.0±3.9 | .086 |
| LVIDd/BSA after adjusted, mm/m2 | – | 28.6 (28.3–28.8) | 28.9 (28.5–29.2) | 28.5 (28.1–28.8) | 28.6 (28.2–29.1) | .446 |
| LVM, g | 158±45 | 150±40 | 159±42 c | 163±45 a | 173±53 a,e | <.001 |
| LVM index, g/m2 | 98±25 | 92±22 | 99±24 a | 100±24 a | 108±24 a,d,f | <.001 |
| LVM index after adjusted, g/m2 | – | 95 (93–97) | 99 (96–102) | 98 (95–101) | 103 a (100–106) | .001 |
| Relative wall thickness | 0.43±0.09 | 0.41±0.08 | 0.43±0.09 c | 0.44±0.09 a | 0.46±0.09 a,d | <.001 |
| Relative wall thickness after adjusted | – | 0.42 (0.41–0.43) | 0.43 (0.42–0.44) | 0.43 (0.42–0.44) | 0.47 b (0.43–0.46) | .016 |
| LVEF, % | 72±7.5 | 73±7.5 | 72±7.4 | 72±7.3 | 72±7.9 | .218 |
| LV geometric category | ||||||
| Normal | 35 | 44 | 34 | 29 | 19 | <.001 |
| Concentric remodeling | 31 | 29 | 30 | 33 | 33 | |
| Concentric hypertrophy | 23 | 16 | 25 | 23 | 36 | |
| Eccentric hypertrophy | 12 | 11 | 12 | 15 | 12 | |
Abbreviations: BP, blood pressure; BSA, body surface area; CVD, cardiovascular disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; Hs‐cTnT, high‐sensitivity cardiac troponin T; LV, left ventricular; LVIDd, left ventricular internal diameter in diastole; LVEF, left ventricular ejection fraction; LVM, left ventricular index; MEave, the average of morning and evening value at home; NT‐proBNP, N‐terminal pro–brain‐type natriuretic peptide; SBP, systolic blood pressure. Data are shown as mean±standard deviation, median (25%–75%), or percentage. P values were calculated by analysis of variance and Tukey's honestly significant differences or χ2 test. Values are expressed as mean (95% confidence interval) and P values were obtained using analysis of covariance, and the Bonferroni test was used for multiple pairwise comparisons or percentages: categories sum up to 100% vertically. a P ≤0.001, b P<0.01, and c P<0.05 vs the lowest category. d P ≤0.001, and e P<0.01 vs the second category. d P ≤0.001, and f P ≤0.001, and g P<0.01 vs the third category.